Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wave Life Sciences ( (WVE) ) has shared an announcement.
On April 28, 2026, Wave Life Sciences reported first quarter 2026 results and highlighted progress across its RNA-based pipeline, led by obesity candidate WVE-007 and AATD therapy WVE-006. The company ended March 31, 2026 with $544.6 million in cash and equivalents, guiding a runway into the third quarter of 2028, which supports multiple mid- and late-stage clinical milestones.
Wave is advancing WVE-007, an INHBE-targeting GalNAc-siRNA for obesity, after Phase 1 INLIGHT data in March 2026 showed sustained total and visceral fat loss with muscle preservation and favorable safety at six months after a single dose. The U.S. Food and Drug Administration has accepted the Phase 2a multidose portion of INLIGHT in higher-BMI individuals, with and without type 2 diabetes, which Wave expects to initiate in the second quarter of 2026 alongside plans for combination and maintenance trials.
For alpha-1 antitrypsin deficiency, WVE-006, a GalNAc-conjugated RNA editing AIMer, has achieved key treatment goals in the RestorAATion-2 trial by restoring protective AAT levels, increasing wild-type M-AAT, and lowering pathogenic Z-AAT, with further 400 mg and 600 mg dose data to be presented at major lung and liver meetings in May 2026. Wave expects additional multidose data in the second half of 2026, which could be pivotal as it seeks regulatory feedback on a potential accelerated approval pathway mid-year.
The company is also expanding its RNA editing franchise with WVE-008 for homozygous PNPLA3 I148M liver disease, supported by preclinical data to be shown at the EASL Congress and a clinical trial application filing planned for 2026. In neuromuscular disease, Wave remains on track to submit a New Drug Application in 2026 for exon 53–skipping DMD candidate WVE-N531 to pursue an accelerated approval pathway with monthly dosing, broadening its late-stage regulatory agenda.
The most recent analyst rating on (WVE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.
Spark’s Take on WVE Stock
According to Spark, TipRanks’ AI Analyst, WVE is a Neutral.
The score is held down primarily by weak financial performance (sharp revenue decline, large losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). These are partially offset by a relatively strong cash runway and positive pipeline/partnership updates from the latest earnings call, which improve near-term funding visibility and upside potential if upcoming data deliver.
To see Spark’s full report on WVE stock, click here.
More about Wave Life Sciences
Wave Life Sciences Ltd., based in Cambridge, Mass., is a clinical-stage biotechnology company focused on RNA medicines, including GalNAc-conjugated siRNAs and RNA editing oligonucleotides. Its pipeline targets metabolic and liver diseases, obesity, and genetic disorders such as alpha-1 antitrypsin deficiency, positioning the company in competitive cardiometabolic and rare disease markets.
Average Trading Volume: 4,096,831
Technical Sentiment Signal: Sell
Current Market Cap: $1.35B
See more insights into WVE stock on TipRanks’ Stock Analysis page.